Annual report pursuant to Section 13 and 15(d)

Income Taxes

v3.20.4
Income Taxes
12 Months Ended
Dec. 31, 2020
Income Tax Disclosure [Abstract]  
Income Taxes

NOTE 13—INCOME TAXES

For the years ended December 31, 2020 and 2019, the Company recorded an income tax provision expense of $5.00 thousand and $0.00, respectively, as reflected in the table below.

A reconciliation of income taxes at the statutory federal income tax rate to net income taxes included in the accompanying statements of operations is as follows (in thousands):

 

 

 

2020

 

 

2019

 

U.S. federal taxes (benefit) at statutory rate

 

$

(22,032

)

 

$

(14,578

)

State federal income tax benefit

 

 

(895

)

 

 

(528

)

Permanent differences

 

 

(46

)

 

 

34

 

Stock compensation

 

 

524

 

 

 

4,112

 

Research and development credits

 

 

(4,043

)

 

 

(1,677

)

Change in valuation allowance due to operations

 

 

26,484

 

 

 

12,756

 

Expiring state carryovers and other

 

 

13

 

 

 

(119

)

Total

 

$

5

 

 

$

 

 

 

The tax effects of temporary differences that give rise to significant components of the net deferred tax assets are as follows (in thousands):

 

 

 

December 31,

 

 

 

2020

 

 

2019

 

Deferred tax assets

 

 

 

 

 

 

 

 

Net operating loss carryforward

 

$

42,029

 

 

$

26,554

 

Research and development credits

 

 

9,066

 

 

 

4,147

 

Deferred stock compensation

 

 

3,260

 

 

 

1,571

 

Deferred revenue

 

 

5,195

 

 

 

1,956

 

Lease liability

 

 

3,045

 

 

 

2,835

 

Other

 

 

1,301

 

 

 

736

 

Total deferred tax assets

 

 

63,896

 

 

 

37,799

 

 

 

 

 

 

 

 

 

 

Total deferred tax liabilities

 

 

 

 

 

 

 

 

Depreciable and amortizable assets

 

 

(1,677

)

 

 

(1,340

)

Right-of-use asset

 

 

(2,344

)

 

 

(2,112

)

R&D intangible assets

 

 

 

 

 

(956

)

Total deferred tax liabilities

 

 

(4,021

)

 

 

(4,408

)

Less: Valuation allowance

 

 

(59,875

)

 

 

(33,391

)

Net deferred tax assets

 

$

 

 

$

 

 

At December 31, 2020, the Company had federal net operating loss carryforwards of approximately $198.8 million available to offset future taxable income and state net operating loss carryforwards of approximately $0.4 million available to offset future taxable income. The Company’s federal net operating loss carryforwards of $62.8 million which will begin to expire in 2024 if not used before such time to offset future taxable income or tax liabilities. The Company’s federal net operating loss carryforwards of $136.0 million which do not expire. A portion of the Company’s net operating loss carryforward is subject to certain limitations on annual utilization in case of changes in ownership, as defined by federal and state tax laws. The annual limitation may result in the expiration of the net operating loss before utilization.

 

At December 31, 2020, the Company had federal research and development tax credits available to offset future taxes of approximately $7.6 million, which expire in the year beginning 2022, and state research and development tax credits of approximately $1.9 million, which expire beginning 2033.

The Company has established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets. The valuation allowance increased by $26.5 million from continuing operations.

 

 

The Company has no uncertain tax positions as of December 31, 2020 and 2019. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company currently has no federal or state tax examinations in progress nor has it had any federal or state tax examinations since its inception. As a result of the Company’s net operating loss carryforwards, all of its tax years are subject to federal and state tax examination.